Dr Andrew Armstrong

0:09:53

Dr. Andrew Armstrong on Precision Medicine Approaches in Advanced Prostate Cancer

0:54:18

Guiding Personalized Treatment for Advanced Prostate Cancer (Andrew Armstrong)

0:01:18

Dr. Armstrong Discusses ARCHES Trial in Prostate Cancer

0:02:09

Andrew Armstrong, MD, on determining treatment of prostate cancer with DNA repair markers

0:00:56

Dr. Armstrong on Sipuleucel-T in Prostate Cancer

0:02:29

ASCO GU 2019 - Dr. Andrew J. Armstrong, Duke University, NC, USA

0:01:29

Andrew Armstrong, MD, provides insight as to genetic testing to be conducted in a patient with mPC

0:02:21

Meet Andrew Armstrong, RN

0:09:23

Drs. Armstrong, Wallis on AI Biomarkers and HRQoL for Localized Prostate Cancer, mCRPC

0:01:14

Dr. Armstrong on Precision Medicine for Metastatic Prostate Cancer

0:01:58

Andrew J. Armstrong, MD, MSc

0:02:19

Andrew J. Armstrong, MD | Duke Health

0:01:18

Andrew Armstrong, MD, discusses the Phase 2 STREAM study in pre-metastatic prostate cancer

0:01:40

Dr. Armstrong on Detection of Chromosomal Defects in mCRPC

0:01:00

Dr. Armstrong on the Utility of Pamiparib and Other PARP Inhibitors in Prostate Cancer

0:02:07

Andrew Armstrong, MD, presents an overview of the ARCHES trial in mHSPC

0:00:57

Dr. Armstrong on the utility of PARP Inhibitors in Mutated Prostate Cancer

0:01:24

Andrew Armstrong, MD, offers opinion on androgen receptor inhibitors

0:01:19

Dr. Armstrong on the Utility of Liquid Biopsies in mCRPC

0:00:58

Andrew Armstrong, MD, on impressions of the CARD study investigating cabazitaxel in mCRPC patients

0:01:04

Andrew Armstrong, MD, shares updates on the ARCHES study investigating enzalutamide in mPC patients

0:01:05

Andrew Armstrong, MD, explains whether ARV-7 is predictive of response to taxanes in mPC patients

0:01:38

Dr. Armstrong Discusses Findings of ARCHES Trial in Prostate Cancer

0:01:57

ASCO #GU19: Poter Walk with Andrew Armstrong, MD, on the #ARCHES Trial